Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
[PDF][PDF] First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for …
A Inoue, K Kobayashi, K Usui, M Maemondo… - J Clin …, 2009 - researchgate.net
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
PURPOSE: Epidermal growth factor receptor (EGFR) mutations have been found in the
majority of gefitinib-responsive non-small cell lung cancer (NSCLC) patients from …
majority of gefitinib-responsive non-small cell lung cancer (NSCLC) patients from …
[PDF][PDF] Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene …
A Inoue, T Suzuki, T Fukuhara, M Maemondo… - J Clin …, 2006 - researchgate.net
Prospective Phase II Study of Gefitinib for Chemotherapy- Naıve Patients With Advanced
Non–Small-Cell Lung Cancer With Epider Page 1 Prospective Phase II Study of Gefitinib for …
Non–Small-Cell Lung Cancer With Epider Page 1 Prospective Phase II Study of Gefitinib for …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …
[HTML][HTML] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
H Asahina, K Yamazaki, I Kinoshita, N Sukoh… - British journal of …, 2006 - nature.com
Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …
[HTML][HTML] Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West …
K Tamura, I Okamoto, T Kashii, S Negoro… - British journal of …, 2008 - nature.com
The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials
BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of …
T Shukuya, T Takahashi, R Kaira, A Ono… - Cancer …, 2011 - Wiley Online Library
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …